Our research and development pipeline The world is changing, providing an opportunity for new ideas, approaches and solutions.
By changing in the right way we maintain and live up to our role as an industry leader but more importantly offer patients medicines and hope of a better life.
Our late stage R&D pipeline now holds the prospect of future Our approach to research growth from LDX the active ingredient in VYVANSE in major and development depressive disorder, binge eating disorder and negative symptoms of schizophrenia.
Our intrathecal programs are also progressing The Company focuses its development resources on projects well as we plan the next clinical trials for Hunter CNS and within its core therapeutic areas of behavioral health, Sanlippo A and continue to enrol MLD patients into the ongoing gastrointestinal, human genetic therapies and regenerative Phase 1 2 trial.
A phase 2b study of SPD602, our product for medicine, as well as early development projects in additional treatment of iron overload, is underway and headline results are therapeutic areas.
Total R&D expenditures of $965.5 million, $770.7 million and $661.5 million were incurred in the years ended December 31, 2012, 2011 and 2010 respectively.
R&D expenditures growth in 2012: Fu ture 25% We put patients ts and and their well being g at the heart of everyt thing we do.
We cen nter our business a around patients served d by specialist phys sicians and will continu ue to do so.
12 12 S Sh Sh Sh Sh Sh Sh Sh Sh Sh Sh S Sh Sh Sh Sh Sh Sh Sh Sh Sh Sh Sh Sh Sh Sh hi hire  re re re re re re re re re re re re re re re r r re re plc plc plc plc plc plc plc plc plc p p p p c c c c c c c A An A An An An An An An An An An An An nnu nua nua nua nua nua nua nua nua nua nua nua nua a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a al l R lR lR lR lR lR lR l R l R l R l R ll R R R R R R Rep ep ep ep ep ep ep ep ep ep ep ep ep ep ep po o o o o o o o o o o o o o o ort rt rt rt rt rt rt rt rt rt rt r rt rt t 20 20 20 20 20 2 20 20 20 20 20 20 20 201 1 1 1 1 1 1 1 1 1 12 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 Overview Our pipeline Increasing number of promising opportunities Preclinical and Approved last Discovery Phase 1 Phase 2 Phase 3 Registration 12 months Broad portfolio SPD554 SPD557 INTUNIV INTUNIV ELVANSE of discovery selective M0003 ADHD ADHD ADHD and preclinical 2A agonist rGERD assets from internal EU Canada EU research HGT2310 SPD602 LDX FIRAZYR DERMAand BD 1 Hunter CNS FerroKin MDD ACE inhibitorGRAFT 4 Iron overload induced AE DFU EU Canada HGT1410 HGT4510 LDX 1 2 Sanlippo A DMD NSS HGT1110 SRM003 LDX 1 MLD Hemodialysis BED Access SPD555 Chronic 3 Constipation US XAGRID Essential ThromSpecialty Pharmaceuticals bocythaemia Human Genetic Therapies Regenerative Medicine Japan Notes ABH001 Lisdexamfetamine dimesylate, active ingredient in VYVANSE ELVANSE.
EB 1 HGT1410, HGT2310 and HGT1110 are currently in Phase 1 2 clinical trials.
4 Application for EU label change filed in December 2012.
